HC Wainwright restated their buy rating on shares of Greenwich LifeSciences (NASDAQ:GLSI – Free Report) in a research report released on Wednesday morning, Benzinga reports. The brokerage currently has a $36.00 price objective on the stock. HC Wainwright also issued estimates for Greenwich LifeSciences’ Q4 2024 earnings at ($0.17) EPS, FY2024 earnings at ($0.75) EPS, […]